PARP1 and cancer: The absence of PINX1 rendered Hela cells susceptible to PARP inhibitors, a phenomenon not only confirmed in OVCAR8, OC316, and BEL7404 cancer cell lines but also validated in vivo in xenograft mouse models (Fig. 2), suggesting PINX1 as a potential target for cancer therapy.